

CITATION REPORT

List of articles citing

Inhibitors in Severe Hemophilia A: 25-Year Experience in Slovakia

DOI: 10.1055/s-0036-1581107

Seminars in Thrombosis and Hemostasis, 2016, 42, 550-62.

Source: <https://exaly.com/paper-pdf/65098232/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
12	Controversies in Inherited Bleeding Disorders. <i>Seminars in Thrombosis and Hemostasis</i> , 2016 , 42, 459-62	5.3	5
11	Current view and outcome of ITI therapy - A change over time?. <i>Thrombosis Research</i> , 2016 , 148, 38-44	8.2	14
10	Product type and other environmental risk factors for inhibitor development in severe hemophilia A. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018 , 2, 220-227	5.1	14
9	The inhibitors - a challenge for the management of patients with hereditary haemophilia A. <i>Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne</i> , 2018 , 56, 143-152	1.5	
8	2019 Eberhard F. Mammen Award Announcements: Part II-Most Popular Articles. <i>Seminars in Thrombosis and Hemostasis</i> , 2019 , 45, 215-224	5.3	3
7	Quantitative HLA-class-II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 201-216	15.4	1
6	2020 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 383-392	5.3	7
5	Clinical Care of Bone Health in Patients on the Immune Tolerance Induction Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020 , 26, 1076029620913951	3.3	3
4	Incidence of inhibitor development in PUPs with severe Haemophilia A in the CEE region between 2005 and 2015. <i>Thrombosis Research</i> , 2021 , 198, 196-203	8.2	2
3	Epidemiological Challenges in Rare Bleeding Disorders: FVIII Inhibitor Incidence in Haemophilia A Patients-A Known Issue of Unknown Origin. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 18,	4.6	2
2	The Impact of Recombinant Versus Plasma-Derived Factor VIII Concentrates on Inhibitor Development in Previously Untreated Patients With Hemophilia A: A 2021 Update of a Systematic Review and Meta-Analysis. <i>Cureus</i> , 2022 ,	1.2	
1	Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysis. 2023 , 7, 100020		0